Presentation is loading. Please wait.

Presentation is loading. Please wait.

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,

Published byNoreen Black Modified over 6 years ago

Similar presentations

Presentation on theme: "Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,"— Presentation transcript:

1 Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla, MD, Allen P. Burke, MD, Alexander Marx, MD, Andrew G. Nicholson, DM, FRCPath  Journal of Thoracic Oncology  Volume 10, Issue 9, Pages (September 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE Panel of Experts at World Health Organization Consensus Meeting at International Agency for Research on Cancer, Lyon France, April, From left to right: Front row: William D. Travis, Andrew G. Nicholson, Alex Marx, Allen Burke, Elisabeth Brambilla, Elaine S. Jaffe, Hiroko Ohgaki; Robert Jakob; Second row: Andre Moreira, Masayuki Noguchi, Edwina Duhig, Sanja Dacic, Francoise Galateau-Salle, Mary Beth Beasley, Ming Sound Tsao, Yasushi Yatabe, Fabio Tavora, Fred Hirsch; Third Row: Alain Borczuk, Nicolas Girard, Philipp Ströebel, Leendert H.J. Looijenga; Cristina Basso, Yuichi Ishikawa, Giuseppe Pelosi, Alberto Marchevsky, Ignacio Wistuba, Joseph J. Maleszewski, Keith Kerr, Marc Ladanyi, Brian Rous. Photograph courtesy of IARC. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart  William D. Travis, MD, Elisabeth Brambilla,"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.
NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,
A Hole in the Heart Journal of Thoracic Oncology

A Hole in the Heart Journal of Thoracic Oncology
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Mary.
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.
The 2015 World Health Organization Classification of Lung Tumors

The 2015 World Health Organization Classification of Lung Tumors
Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Ming-Sound Tsao, MD, FRCPC, William D

Ming-Sound Tsao, MD, FRCPC, William D
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 

Similar presentations

Ads by Google